KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
about
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsPrognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-AnalysisProgress in acute myeloid leukemiaPhase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaCBFbeta is critical for AML1-ETO and TEL-AML1 activity.Systemic mastocytosis: a rare case of increased liver stiffness.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.A novel melting curve-based method for detecting c-kit mutations in acute myeloid leukemia.Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasPrognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells.Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisMutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaMastocytosis: state of the art.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicMolecular diagnostics in acute leukemias.High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the makingKIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.Characterization of Leukemia-Inducing Genes Using a Proto-Oncogene/Homeobox Gene Retroviral Human cDNA Library in a Mouse In Vivo Model.Overexpression and knockout of miR-126 both promote leukemogenesisCurrent therapeutic strategies for acute myeloid leukaemia.Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantationCentral review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experiencePotential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLCytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cellsPrognostic markers in AML: focus on CBFLHLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.
P2860
Q24685914-A58EDA7D-E3E5-4AF0-986C-BD0225A5BCFEQ26740953-29FEFC92-B9ED-4EFA-82EC-C06824226011Q26771740-A4E50A08-5B48-42F6-B7AB-8395870182ECQ27024006-1504BAD5-FF13-414F-91D3-485FF1F3CF2BQ28271726-2FBFB16A-43D5-4A7D-AA76-E316B279FF0EQ30439864-D1171A3D-20E9-49AB-93A5-884B0B50C5E7Q33418580-ECED8D1F-FA9E-432D-8CCC-A51F90DFE298Q33421005-ED427E6B-40DC-4EFD-8566-E0E55DE76445Q33754603-5BE2A411-73A0-4C21-9A9C-F6BF7C1D0FF9Q33778329-FAA60EB4-2D2B-4A9C-89A5-44EE9955B0A9Q34169601-7A4312C6-7979-4FB8-8E86-F52F000CFEB6Q34285937-0F0B7B9C-9384-4709-B14E-415FD472FD95Q34287371-89FEC3B5-466F-423A-975E-CBD104D34C35Q34335004-A4025C0D-81F5-4153-B4CD-38586462D5EDQ34428556-2120D31A-4C56-4798-B187-0F795FE31870Q34578265-64B31C2C-C71B-4368-A174-B606EEED3BC6Q34578418-D229860E-A811-49A5-ABCA-0E1DC3E39900Q34598109-13B29B20-714B-443E-A815-0B93C7CE0E76Q34641105-BFC82C99-B307-4F8E-9DB2-1007E3164C1EQ34663691-EA8F05FE-DC2F-4589-B992-DA2370C40D91Q34764504-2DCE541B-FB67-4571-BCC6-82523AE342D2Q34817365-2D8D70AB-31F5-497A-8E57-A25F1C2E5D74Q35007333-952A59ED-60E9-4630-B2E8-18AD5D6C11F3Q35361598-784E8910-E4B7-4B1D-A31F-CDDE8911B455Q35642451-14537B14-16D1-4F6D-A09B-3586C39C62CAQ35776437-336FEF7A-D096-4C0A-995B-60C36C244BFAQ35776442-72C5DC20-92EC-44E6-941B-34F70537963BQ35852567-FA035DBF-DEC5-4057-9821-0E8A803A2B86Q36193187-634DE4A5-E685-40F5-B81D-B412C533A6BCQ36539598-6D450344-951D-4E11-AFFF-06EE41DD6687Q36591394-5B43E210-686B-4A6F-A2D4-42EEE8236BEBQ36660483-E7AE42E0-F259-4F1D-B803-E166C62638CAQ36713551-2EA8A7BB-0DC2-48CB-BCE7-79A7A6966106Q36797201-1E35CCEC-69F3-435A-865C-3FE156840492Q36808186-925C29D8-A583-40AD-8A7D-18E34256F644Q36843769-A2174C4D-8CDE-45BA-88A9-40AC3A1EF437Q36852251-4F27D3E7-4110-4530-9172-68B49B60222FQ36865630-E2F2CA2F-0456-4E31-9ADD-A275D210FE53Q36919799-94BBA5D3-2037-4F46-8D29-BD081FB86726Q37200775-E9742564-F316-4A97-88F5-721129C2FE52
P2860
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
KIT-D816 mutations in AML1-ETO ...... ent-free and overall survival.
@en
type
label
KIT-D816 mutations in AML1-ETO ...... ent-free and overall survival.
@en
prefLabel
KIT-D816 mutations in AML1-ETO ...... ent-free and overall survival.
@en
P2093
P50
P1433
P1476
KIT-D816 mutations in AML1-ETO ...... ent-free and overall survival.
@en
P2093
Karsten Spiekermann
Tobias M Kohl
Wolfgang Hiddemann
Wolfgang Kern
P304
P356
10.1182/BLOOD-2005-04-1466
P407
P577
2005-10-27T00:00:00Z